News

A new commentary published in npj Mental Health Research raises questions about a widely cited meta-analysis comparing ketamine and psilocybin therapy. Author Ramūnas Janavičius points

New research from Washington University School of Medicine (led by pharmacologist Tao Che) found that ketamine directly binds to and activates opioid receptors, not just

What if the traditional view of depression—a simple imbalance of serotonin—was wrong? In this episode of Learning and Living STEMM in Connecticut, host Tanimu Deleon

In the year 2000, psychiatry experienced one of the most important breakthroughs in decades: researchers showed that ketamine, a widely used anesthetic, could produce a

May is Mental Health Awareness Month — a time to open up conversations we often keep quiet. If you or someone you love has been

This article examines the evolving understanding of depression and the mechanisms behind ketamine’s antidepressant effects. It discusses the shift away from the traditional “chemical imbalance”

A recent study published on PubMed highlights promising findings in the treatment of depression using intranasal ketamine. Researchers found that racemic ketamine is non-inferior to

Telehealth ketamine therapy provider Mindbloom is facing a wrongful-death lawsuit after a 27-year-old male patient died from ketamine toxicity in October 2023, allegedly while under

For over 50 years, ketamine has been known as a safe anesthetic, and at lower doses, an effective treatment for depression. Emerging research suggests it

A retrospective study of 153 patients with severe treatment-resistant depression found that twice-weekly IV ketamine over 4–5 weeks led to faster and greater symptom reduction

A four-year Cleveland Clinic study of 1,034 patients found that low-dose ketamine infusions significantly improved pain, sleep, and daily function for 20%–46% of people with

A Cleveland Clinic study found that low-dose IV ketamine infusions are safe and effective for chronic pain management. Among more than 1,000 patients, 20%–46% saw

Ketamine has emerged as a promising treatment for suicidal ideation (SI) in patients with major depressive disorder (MDD), showing rapid and sustained reductions in suicidality.

A new Journal of Clinical Psychiatry study from the Mayo Clinic found that ketamine and esketamine treatment can significantly reduce emergency department visits related to

This study followed 135 patients with severe depression—110 with treatment-resistant major depressive disorder (TRD) and 25 with treatment-resistant bipolar depression (TRBD)—who had already responded to